Detalles de la búsqueda
1.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
N Engl J Med;
386(11): 1034-1045, 2022 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35294813
2.
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis;
83(4): 475-487, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129117
3.
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ann Rheum Dis;
2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754981
4.
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes.
Ann Rheum Dis;
82(7): 927-936, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085289
5.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Ann Rheum Dis;
81(7): 951-961, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338035
6.
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Ann Rheum Dis;
81(7): 962-969, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35580976
7.
Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature.
Ann Rheum Dis;
81(10): 1428-1437, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35710306
8.
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Ann Rheum Dis;
2022 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477518
9.
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ann Rheum Dis;
81(11): 1541-1548, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35944946
10.
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ann Rheum Dis;
81(3): 370-378, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34911705
11.
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Ann Rheum Dis;
81(8): 1143-1150, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338033
12.
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
Rheumatology (Oxford);
60(11): 5379-5389, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33547784
13.
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
Lupus;
30(8): 1254-1263, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33977796
14.
Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus.
J Am Acad Dermatol;
84(6): 1562-1567, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32682879
15.
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.
J Allergy Clin Immunol;
146(6): 1419-1433, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32446964
16.
Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans.
Hum Mol Genet;
27(21): 3813-3824, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30085094
17.
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.
Ann Rheum Dis;
79(3): 356-362, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31915121
18.
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
J Autoimmun;
106: 102340, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31629628
19.
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
Rheumatology (Oxford);
59(10): 2930-2938, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107560
20.
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.
Rheumatology (Oxford);
58(7): 1259-1267, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30753683